AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10197566 — intervention group
Group type: COMPARATOR
Intervention: 23 RE (75 IU)/d (trace group)
Number of subjects: 146
Study 7790695 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (500 mg daily for 1 year)
Number of subjects: 67
Study 7790695 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical appearance tablets for 1 year)
Number of subjects: 67
Study 7790695 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E and Placebo
Number of subjects: 67
Study 2193075 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ASA 500 mg suppositories (Asacol) 3 times a day for 1 month
Number of subjects: 62
Study 2193075 — intervention group
Group type: COMPARATOR
Intervention: Placebo given in the same regime
Number of subjects: 62
Study 154749 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural oestrogen preparation (piperazine oestrone sulphate)
Number of subjects: 0
Study 154749 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine (control group)
Number of subjects: 0
Study 30952794 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 220 mg twice daily
Number of subjects: 195
Study 30952794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 29150738 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-mediated intervention for young children with autism
Number of subjects: 0
Study 29150738 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism Family Experience Questionnaire (AFEQ)
Number of subjects: 0
Study 27213493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 84
Study 24333490 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1264
Study 24333490 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 1264
Study 22708885 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-distanced perspective
Number of subjects: 0
Study 22708885 — intervention group
Group type: COMPARATOR
Intervention: Self-immersed perspective
Number of subjects: 0
Study 20178617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Individual Intervention (III)
Number of subjects: 287
Study 20178617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Group Intervention (IGI)
Number of subjects: 287
Study 20178617 — intervention group
Group type: COMPARATOR
Intervention: Minimal Intervention (MI)
Number of subjects: 287
Study 18401214 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 610
Study 16095054 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 13
Study 16095054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 16095054 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 13
Study 12074225 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic methods of evidence-based medicine
Number of subjects: 45
Study 12074225 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of quality of evidence
Number of subjects: 45
Study 10024849 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery (ER) trial - cooling with a high velocity fan during recovery periods
Number of subjects: 12
Study 10024849 — intervention group
Group type: COMPARATOR
Intervention: Normal Recovery (NR) trial - no cooling during recovery periods
Number of subjects: 12
Study 7479624 — intervention group
Group type: EXPERIMENTAL
Intervention: Social marketing theory (SMT) recruitment materials in Treatment Hall
Number of subjects: 1433
Study 7479624 — intervention group
Group type: COMPARATOR
Intervention: Usual Care recruitment materials in Control Hall
Number of subjects: 1433
Study 2265248 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrates (PCC)
Number of subjects: 11
Study 2265248 — intervention group
Group type: COMPARATOR
Intervention: Purified factor IX concentrate
Number of subjects: 11
Study 2265248 — intervention group
Group type: EXPERIMENTAL
Intervention: Both concentrates
Number of subjects: 11
Study 7033426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (200 mg intramuscularly each week)
Number of subjects: 33
Study 31525220 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized avatar body
Number of subjects: 2
Study 31525220 — intervention group
Group type: COMPARATOR
Intervention: Abstract cube that responded to their movements
Number of subjects: 2
Study 31525220 — intervention group
Group type: COMPARATOR
Intervention: Artificial 'pseudosynchrony' dataset
Number of subjects: 2
Study 27687519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancient grain bread
Number of subjects: 45
Study 27687519 — intervention group
Group type: COMPARATOR
Intervention: Modern grain bread
Number of subjects: 45
Study 27687519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancient grain bread (Verna variety)
Number of subjects: 45
Study 23907693 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear lesions (LL)
Number of subjects: 28
Study 23907693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 28
Study 23907693 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + LL
Number of subjects: 28
Study 23522799 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g/d n‐3 (1.08g eicosapentoaenoic acid + 0.72 g docosahexaenoic acid)
Number of subjects: 45
Study 23522799 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g/d walnut
Number of subjects: 45
Study 23522799 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g/d conjugated linoleic acid (CLA)
Number of subjects: 45
Study 20360492 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil and propofol (R&P)
Number of subjects: 40
Study 20360492 — intervention group
Group type: COMPARATOR
Intervention: Morphine and midazolam (M&M)
Number of subjects: 40
Study 19212858 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate (CH) 10 g daily for 6 months
Number of subjects: 250
Study 19212858 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 250
Study 18681246 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-year randomized control trial of different models of service provision
Number of subjects: 11
Study 16124971 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplex AF cement (high-viscosity)
Number of subjects: 39
Study 16124971 — intervention group
Group type: COMPARATOR
Intervention: Simplex P cement (low/medium viscosity)
Number of subjects: 39
Study 11880904 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvastus approach
Number of subjects: 19
Study 11880904 — intervention group
Group type: COMPARATOR
Intervention: Medial parapatellar approach
Number of subjects: 19
Study 11864500 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I inactivated vaccine against HFRS
Number of subjects: 401
Study 11864500 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 401
Study 8668427 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive method of estimation
Number of subjects: 92
Study 8668427 — intervention group
Group type: COMPARATOR
Intervention: Verbal method of estimation
Number of subjects: 92
Study 8668427 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex physical tasks (e.g., ball throws)
Number of subjects: 92
Study 8668427 — intervention group
Group type: EXPERIMENTAL
Intervention: Pace of task performance (slow vs rapid)
Number of subjects: 92
Study 2774039 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep cauterization of the punctum and vertical canaliculus
Number of subjects: 23
Study 2774039 — intervention group
Group type: COMPARATOR
Intervention: Superficial cauterization of the punctum only
Number of subjects: 23
Study 362893 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (12 mg/kg/day for 10 days)
Number of subjects: 118
Study 362893 — intervention group
Group type: COMPARATOR
Intervention: Sulfamethoxazole (50 mg/kg/day for 10 days)
Number of subjects: 118
Study 362893 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 118
Study 362893 — intervention group
Group type: COMPARATOR
Intervention: Sulfamethoxazole
Number of subjects: 118
Study 30626906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40IU)
Number of subjects: 30
Study 30626906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28480382 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation
Number of subjects: 24
Study 25548103 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood sampling using HemoCue WBC DIFF system
Number of subjects: 73
Study 25548103 — intervention group
Group type: COMPARATOR
Intervention: Venous blood sampling
Number of subjects: 73
Study 25548103 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood sampling
Number of subjects: 73
Study 23301057 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole and Everolimus
Number of subjects: 81
Study 23301057 — intervention group
Group type: COMPARATOR
Intervention: Letrozole and Placebo
Number of subjects: 81
Study 23301057 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus alone (pre-surgical)
Number of subjects: 81
Study 21052022 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker or diuretic monotherapy
Number of subjects: 5152
Study 21052022 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker or diuretic-based treatment
Number of subjects: 5152
Study 21052022 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem-based treatment
Number of subjects: 5152
Study 19319994 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication or interpersonal therapy (RCT participants, n=105)
Number of subjects: 256
Study 19319994 — intervention group
Group type: COMPARATOR
Intervention: Clinic patients (n=151)
Number of subjects: 256
Study 19319994 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT participants (n=105)
Number of subjects: 256
Study 17401733 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized amino acid mixture plus Remeron
Number of subjects: 40
Study 17401733 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Remeron
Number of subjects: 40
Study 15554569 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualized group-based intervention (weekly 90-min sessions over 6 weeks)
Number of subjects: 63
Study 15554569 — intervention group
Group type: COMPARATOR
Intervention: Single educational session (control condition)
Number of subjects: 63
Study 11133640 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (25 mg IV)
Number of subjects: 60
Study 11133640 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg IV)
Number of subjects: 60
Study 11133640 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (25 mg IV)
Number of subjects: 60
Study 9643276 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12.5 mg t.i.d.)
Number of subjects: 40
Study 9643276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7881026 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 79
Study 7881026 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 79
Study 3144541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 600 mg
Number of subjects: 20
Study 3144541 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 3 g
Number of subjects: 20
Study 31563358 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodynamic exercises (EEN)
Number of subjects: 0
Study 31563358 — intervention group
Group type: COMPARATOR
Intervention: Extension-oriented exercises (EE)
Number of subjects: 0
Study 28606503 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation manipulation intervention (EXPECT)
Number of subjects: 124
Study 28606503 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive therapy (SUPPORT)
Number of subjects: 124
Study 28606503 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care alone (SMC)
Number of subjects: 124
Study 26165739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincterotomy
Number of subjects: 214
Study 26165739 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 214
Study 26165739 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary sphincterotomy
Number of subjects: 214
Study 26165739 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual sphincterotomy
Number of subjects: 214
Study 23412407 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive lateral approach
Number of subjects: 50
Study 23412407 — intervention group
Group type: COMPARATOR
Intervention: Conventional lateral approach
Number of subjects: 50
Study 21196758 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiao-Feng-San (XFS)
Number of subjects: 71
Study 21196758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 18303486 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg nebicapone
Number of subjects: 19
Study 18303486 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg nebicapone
Number of subjects: 19
Study 18303486 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg entacapone
Number of subjects: 19
Study 18303486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16782911 — intervention group
Group type: EXPERIMENTAL
Intervention: RT/PCV (radiotherapy followed by six cycles of standard procarbazine, lomustine, and vincristine chemotherapy)
Number of subjects: 368
Study 16782911 — intervention group
Group type: COMPARATOR
Intervention: RT only (59.4 Gy of radiotherapy in 33 fractions)
Number of subjects: 368
Study 14653888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (3 mg single dose)
Number of subjects: 460
Study 14653888 — intervention group
Group type: COMPARATOR
Intervention: Goserelin (single dose depot preparation)
Number of subjects: 460
Study 14653888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Number of subjects: 460
Study 14653888 — intervention group
Group type: COMPARATOR
Intervention: Goserelin
Number of subjects: 460
Study 10995804 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography plus physical examination
Number of subjects: 39405
Study 10995804 — intervention group
Group type: COMPARATOR
Intervention: Physical examination only
Number of subjects: 39405
Study 9772422 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention
Number of subjects: 34
Study 9772422 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 34
Study 9772422 — intervention group
Group type: COMPARATOR
Intervention: Normal control
Number of subjects: 34
Study 1356328 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III antiarrhythmics
Number of subjects: 0
Study 1356328 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 1356328 — intervention group
Group type: COMPARATOR
Intervention: Class I antiarrhythmics
Number of subjects: 0
Study 2880811 — intervention group
Group type: EXPERIMENTAL
Intervention: Suanzaorentang (250 mg t.i.d.)
Number of subjects: 0
Study 2880811 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (2 mg t.i.d.)
Number of subjects: 0
Study 2880811 — intervention group
Group type: EXPERIMENTAL
Intervention: Suanzaorentang (250 mg t.i.d.) and Diazepam (2 mg t.i.d.)
Number of subjects: 0
Study 30148669 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based training program on HIV prevention and PrEP
Number of subjects: 0
Study 23819593 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP) - Transbond Plus SEP, 3M Unitek
Number of subjects: 57
Study 23819593 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-step etch and primer method (CM) - 37% phosphoric acid
Number of subjects: 57
Study 24041638 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted head extension during tracheal intubation
Number of subjects: 68
Study 24041638 — intervention group
Group type: COMPARATOR
Intervention: Without assisted head extension during tracheal intubation
Number of subjects: 68
Study 20805528 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (100 mg/kg per day)
Number of subjects: 50
Study 20805528 — intervention group
Group type: COMPARATOR
Intervention: Placebo (untreated group)
Number of subjects: 50
Study 18280726 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) during constant workload exercise (CWLE) tests at 75% Pmax
Number of subjects: 18
Study 18280726 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) during exercise
Number of subjects: 18
Study 18280726 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) during maximal exercise (MWLE)
Number of subjects: 18
Study 16166842 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 50
Study 16166842 — intervention group
Group type: COMPARATOR
Intervention: Nonobese patients
Number of subjects: 50
Study 12711664 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish version of the Readiness to Change Questionnaire (RTCQ)
Number of subjects: 165
Study 11186501 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT with 150 patients per group
Number of subjects: 10000
Study 11186501 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT with 400 patients per group
Number of subjects: 10000
Study 11186501 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-sized RCTs
Number of subjects: 10000
Study 8866037 — intervention group
Group type: EXPERIMENTAL
Intervention: One 7 day 17 beta-estradiol transdermal delivery system (TDS)
Number of subjects: 24
Study 8866037 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 7 day 17 beta-estradiol transdermal delivery systems (TDSs)
Number of subjects: 24
Study 1310913 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg daily for 6 months
Number of subjects: 12
Study 1310913 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg daily for 6 months
Number of subjects: 12
Study 1310913 — intervention group
Group type: COMPARATOR
Intervention: Placebo after 6 months of active treatment
Number of subjects: 12
Study 6338722 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 185
Study 6338722 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 185
Study 30826761 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg daily) in combination with isoniazid (H), rifampicin (R), ethambutol (E), and pyrazinamide (Z) for the first 2 months, followed by HRE for 4 months.
Number of subjects: 0
Study 30826761 — intervention group
Group type: COMPARATOR
Intervention: Standard 6-month anti-TB treatment regimen (HRZE) for the first 2 months, followed by HRE for 4 months.
Number of subjects: 0
Study 28489273 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minoxidil 5% applied twice daily
Number of subjects: 45
Study 28489273 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level light therapy (LLLT) using the helmet iGrow® device for 25 minutes 3 days weekly
Number of subjects: 45
Study 28489273 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of topical minoxidil 5% twice daily and LLLT for 25 minutes 3 days weekly for 4 months
Number of subjects: 45
Study 28489273 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 25851492 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/lobaplatin (TL)
Number of subjects: 68
Study 25851492 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/5-fluorouracil (PF)
Number of subjects: 68
Study 24461320 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial weight loss program (Weight Watchers)
Number of subjects: 169
Study 24461320 — intervention group
Group type: COMPARATOR
Intervention: Limited support from health professionals (Control)
Number of subjects: 169
Study 22988653 — intervention group
Group type: EXPERIMENTAL
Intervention: clindamycin phosphate 1.2%‐‐benzoyl peroxide (BPO) 2.5% gel
Number of subjects: 21
Study 22988653 — intervention group
Group type: COMPARATOR
Intervention: adapalene 0.1%‐‐BPO 2.5% gel
Number of subjects: 21
Study 18817886 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions (IIs) during a go no-go task
Number of subjects: 42
Study 18817886 — intervention group
Group type: COMPARATOR
Intervention: Standard instruction during a go no-go task
Number of subjects: 42
Study 18817886 — intervention group
Group type: COMPARATOR
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 42
Study 18817886 — intervention group
Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 42
Study 18005286 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% hydrogen peroxide (HP) bleaching solution
Number of subjects: 61
Study 18005286 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% hydrogen peroxide (HP) bleaching solution
Number of subjects: 61
Study 18005286 — intervention group
Group type: COMPARATOR
Intervention: 10% carbamide peroxide (CP) product
Number of subjects: 61
Study 15329583 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control of BIS using isoflurane
Number of subjects: 23
Study 15329583 — intervention group
Group type: COMPARATOR
Intervention: Manual control of BIS using isoflurane
Number of subjects: 23
Study 15627777 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Burch colposuspension
Number of subjects: 52
Study 15627777 — intervention group
Group type: COMPARATOR
Intervention: Laparotomic Burch colposuspension
Number of subjects: 52
Study 10354808 — intervention group
Group type: EXPERIMENTAL
Intervention: Full sleep deprivation (no sleep on the night before testing)
Number of subjects: 64
Study 10354808 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (restriction to 4 h sleep before testing)
Number of subjects: 64
Study 10354808 — intervention group
Group type: COMPARATOR
Intervention: Alcohol treatment (mean blood alcohol content = 0.07%)
Number of subjects: 64
Study 7551999 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 1292
Study 7551999 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominoperineal resection with preoperative radiotherapy
Number of subjects: 1292
Study 7551999 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincter-saving procedures
Number of subjects: 1292